At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 44 enrolled
Drug / intervention
Ofatumumabdrug
Likely dose
Ofatumumab 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ofatumumab Early Treatment for High-Risk Treatment-Naive, Early Stage (0-II) Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
In Brief
A Phase 2 clinical trial evaluating Ofatumumab for Chronic Lymphocytic Leukemia. Completed, enrolled 44 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn if ofatumumab can help to control CLL/SLL that has not yet been treated. The safety of this drug will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Lymphocytic Leukemia
CountriesUnited States
CollaboratorsGlaxoSmithKline
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2010
Enrollment StartMar 2011
Primary CompletionMar 2023
TodayJul 2026
First PostedNov 18, 2010
Enrollment StartMar 1, 2011
Primary CompletionMar 28, 2023
TodayJul 2, 2026
Enrollment to primary: 12.1 yearsPosted 15.6 years ago
Interventions
Ofatumumabdrug
Loading first dose 300 mg by vein on Day 1 of Cycle 1; and full dose 1000 mg over 4 hours 1 time each week for 7 additional weekly doses (8 doses).